Latest Bladder Cancer News
An interview with David J. McConkey, PhD
Radical cystectomy is associated with better long-term overall survival than trimodal therapy, new study shows.
Use of the monoclonal antibody was associated with a 27% lower risk of death versus chemotherapy.
Finding contrasts with results of randomized clinical trials.
Nomograms specific to radical cystectomy currently do not exist to aid stratification of a patient's risks for complications.
Survey finds that 46% of radiation oncologists have administered ART to patients with muscle-invasive bladder cancer on at least one occasion.
A neutrophil-to-lymphocyte ratio below 3.09 is associated with significantly longer overall and disease-specific survival.
The drug is indicated for treating patients with locally advanced or metastatic disease that progresses despite platinum-containing chemotherapy.
During a median followup of 3.6 and 3.0 years intravesical recurrence developed in 4 (12.5%) and 59 men (30.1%) with and without androgen suppression therapy, respectively.
In a study, 53.1% of patients had concomitant prostate cancer in radical cystectomy specimens.
ASS1 loss occurs in invasive bladder cancer and is targetable by ADI-PEG 20.
After analyzing new data, the FDA again warns that the diabetes drug may be associated with an increased risk for bladder cancer.
Before and after radical cystectomy, thromboembolic events are common in bladder cancer patients who undergo neoadjuvant chemotherapy.
Low levels of vitamin D in the blood may prevent the cells within the bladder from stimulating an adequate response to abnormal cells.
Predictors of distant recurrences after robot-assisted radical cystectomy were mainly dictated by pathological tumor characteristics.
Based on a small study, investigators report encouraging efficacy and safety.
Renal and Urology News Articles
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)